This observation is consistent with our recently published studies demonstrating that immunization with a subunit vaccine consisting of SA-4-1BBL and human papilloma virus E7 TAA in a cervical cancer mouse model resulted in significant reduction in CD4+CD25+FoxP3+ Treg cells, which was correlated with robust therapeutic efficacy [12], [13]. Here, FOXP3 is linked to cervical carcinoma.